Bayer settles Serenade-related litigation with Bion Tech Inc.
Bayer CropScience and Bion Tech, Taiwan, Republic of China, a producer of biological crop protection agents, have settled a patent infringement case in Korea. Under the settlement, Bayer CropScience granted Bion Tech a royalty-bearing license to sell lipopeptide-containing products based on Bion Tech’s proprietary Bacillus subtilis Y1336 strain. Bion Tech´s strain Y1336 produces agrastatin, which is covered by claims related to lipopeptides in Bayer CropScience’s patent portfolio. These lipopeptides contribute to the unique properties of Bayer’s Serenade™ products. The license extends to various countries, with a focus on Asia. Financial terms of the settlement were not disclosed.
Mike Miille, Head of Business Management Biologics at Bayer CropScience, commented: "Biologicals play a significant role in shaping farming´s future because they help to increase yield and optimize grower´s flexibility." Bayer CropScience remains committed to investing in research and development to offer farmers worldwide integrated crop protection solutions combining seeds, chemical and biological crop protection products, as well as services and product stewardship measures. "Strong patent protection is the basis for this innovation," Miille added.
- Phomopsis stem canker in sunflowers
- Conference to help companies take next steps in eBusiness
- Energy for growing crops is large part of farm operating costs
- Moves in livestock futures bracketed those of the crop markets
- 3D Robotics launches new 3DR mapping platforms
- Report finds ag employers can’t fill STEM jobs
- How much corn can the ethanol industry use?
- USDA releases 2012 cash rents data report
- Commentary: Government wants farmers to quit farming
- Economist: Taxing P could reduce risk of algal blooms
- Resistant weeds not controlled by fall residuals
- Do you think the term “agricultural sustainability” is as strong of a buzzword and emphasis for action in the industry as it was 3 years ago?